Review of the safety, efficacy, and pharmacokinetics of elvitegravir with an emphasis on resource-limited settings

Integrase inhibitors represent an important new class of antiretroviral drugs. Elvitegravir, the second available integrase inhibitor to be submitted for regulatory approval appears to be a promising once-daily agent when combined with other antiretroviral drugs. Elvitegravir has demonstrated good e...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Janice Soo Fern, Calmy, Alexandra, Andrieux-Meyer, Isabelle, Ford, Nathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280623/
https://www.ncbi.nlm.nih.gov/pubmed/22347806
http://dx.doi.org/10.2147/HIV.S20993

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3280623/
https://www.ncbi.nlm.nih.gov/pubmed/22347806
http://dx.doi.org/10.2147/HIV.S20993

Ejemplares similares